Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk

Annals of Medicine

Volumn 42, Issue 8, 2010, Pages 562-575

  Lpez Cuenca, Ngel ^a   Marn, Francisco ^a   Roldn, Vanessa ^b   Gonzlez Conejero, Roco ^c   Hernndez Romero, Diana ^a   Valdés, Mariano ^a   Lip, Gregory Y H ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fi brillation; genetic polymorphisms; stroke; thromboembolism

Indexed keywords

ACENOCOUMAROL; ANNEXIN; ANTICOAGULANT AGENT; ANTIVITAMIN K; COUMARIN DERIVATIVE; FIBRINOGEN; WARFARIN;

ANTICOAGULATION; DRUG EFFECT; DRUG METABOLISM; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE FUNCTION; THROMBOEMBOLISM;

EID: 78249279636     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.507601     Document Type: Review

References (146)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fi brillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-52.
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257-354.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifi cation schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
4. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fi brillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-56.
5. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE; for the ATRIA Study Group. Comparison of risk stratifi cation schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810-5.
6. Lip GYH. The prothrombotic state in atrial fibrillation: The atrium, the endothelium and tissue factor? Thromb Res. 2003;111:133-5
7. Marín F, Roldán V, Tello A, Lip GY. Genetic polymorphisms and thromboembolic risk in atrial fibrillation. J Thromb Thrombolysis. 2004;18:151-2.
8. Pengo V, Filippi B, Biasiolo A, Pegoraro C, Noventa F, Iliceto S. Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. Am J Cardiol. 2002;90:545-7.
9. Poli D, Antonucci E, Cecchi E, Betti I, Valdré L, Mugnaini C, et al. Thrombophilic mutations in high-risk atrial fi brilla-tion patients: high prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism. Thromb Haemost. 2003;90:1158-62.
10. Go AS, Reed GL, Hylek EM, Phillips KA, Liu L, Henault LE, et al. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Thromb Thrombolysis. 2003;15:41-6.
11. Carter AM, Catto AJ, Grant PJ. Association of the α-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation. 1999;99:2423-6.
12. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992;45:704-6.
13. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003;13:247-52.
14. Chiang CW, Lo SK, Kuo CT, Cheng NJ, Hsu TS. Nonin-vasive predictors of systemic embolism in mitral stenosis. An echocardiographic and clinical study of 500 patients. Chest. 1994;106:396-9.
15. Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F, Tavazzi L. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J. 1996;17:1381-9.
16. Virchow R. Phlogose und thrombose im Gera β system. In: Virchow R, editor. Gesammelte Abhandlungen zur wissen-chaftlichen Medizin. Frankfurt: Von Meidinger Sohn: 1856. p. 458-636.
17. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997;77:407-11.
18. Lip GYH. Hypercoagulability and haemodinamic abnormalities in atrial fibrillation. Heart. 1997;77:395-6.
19. Lip GYH, Gibbs CR. Does heart failure confer a hyperco-aguble state? Virchow ' s triad revisited. J Am Coll Cardiol. 1999;33:1424-6.
20. Secchi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fi brinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension. 2000;36:978-85.
21. Marín F, Roldán V, Monmeneu JV, BodíV, Fernández C, García de Burgos F, et al. Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. Am J Cardiol. 1999; 84:862-4.
22. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73: 527-33.
23. Lip GYH, Lip PL, Zafiris J, Watson RDS, Lowe GDO. Fibrin D-dimer and beta-thromboglobulin as a markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation. 1996;94:425-31.
24. Feng D, D'Agostino RB, Silbershatz H, Lipinska I, Massaro J, Levy D, et al. Haemostatic state and atrial fibrillation (The Framingham Offspring Study). Am J Cardiol. 2001;87: 168-71.
25. Furui H, Taniguchi N, Yamauchi K, Sotobata I, Saito H, Inagaki H. Effects of treadmill exercise on platelet function, blood coagulability and fi brinolytic activity in patients with atrial fibrillation. Jpn Heart J. 1987;28:177-84.
26. Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotani C, et al. Prothrombin fragment F1 +2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis. 1992;3:469-73.
27. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1990;16:377-80.
28. Blann AD, Lip GYH. The endothelium in atherothrom-botic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis. 1998;9: 297-306.
29. Blann AD, Lip GYH. Is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997;128:135-8.
30. Feinberg WM, Macy E, Cornell ES, Nightingale SD, Pearce LA, Tracy RP, et al. Plasmin-a2-antiplasmin complex in patients with atrial fibrillation. Thromb Haemost. 1999; 82:100-3
31. Marín F, Roldán V, Marco P, Martínez JG, Toral A, García de Burgos F, et al. Improvement of fi brinolytical function in chronic rheumatic atrial fibrillation after anticoagulation. Rev Esp Cardiol. 1999;52:25-30
32. Roldán V, Marín F, Marco P, Martínez JG, Calatayud R, Sogorb F. Hypofi brinolysis in atrial fibrillation. Am Heart J. 1998;136:956-60.
33. Blann AD, Dobrotova M, Kubisz P, McCollum CN. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626-30.
34. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, et al. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behaviour with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol. 1992;4:32-9.
35. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fi bril-lation. Am J Cardiol. 2004;94:805-7.
36. Maclean PS, Tait RC, Rumley A, Mcmahon AD, Lowe GD. Anticoagulation with warfarin downregulates infl amma-tion. J Thromb Haemost. 2003;1:1838-9.
37. Marin F, Roldan V, Climent V, Garcia A, Marco P, Lip GYH. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor TIMP-1? Stroke. 2003; 34:1181-6.
38. Kamath S, Blann AD, Lip GYH. Platelets and atrial fibrillation. Eur Heart J. 2001;22:2233-42.
39. Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GYH. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke. 2002;33:2187-91.
40. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, et al. Tissue factor expression in atrial endothelia associated with non-valvular atrial fi brilla-tion: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003;111:137-42.
41. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GYH. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J. 2000; 140:777-84.
42. Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombo-genesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001;37:1436-42
43. Ariëns RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ. Activation markers of coagulation and fi bri-nolysis in twins: heritability of the prethrombotic state. Lancet. 2002;359:667-71.
44. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I: structure, distribution, activation, and function. Crit Rev Clin Lab Sci. 1996;33: 357-421.
45. Baumann RE, Henschen AH. Human fi brinogen polymorphic site analysis by restriction endonuclease digestion and allele-specifi c polymerase chain reaction amplifi cation: identifi cation of polymorphisms at positions Aa312 and Bb448. Blood. 1993;82:2117-24.
46. Thomas A, Green F, Kelleher C, Wilkes HC, Brennan PJ, Meade TW, et al. Variation in the promotor region of the ß fi brinogen gene is associated with plasma fi brinogen levels in smokers and non-smokers. Thromb Haemost. 1991;65: 487-90.
47. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk. 1995;2:197-205.
48. DiMinno G, Mancini M. Measuring plasma fi brinogen to predict stroke and myocardial infarction. Arteriosclerosis. 1990;10:1-7.
49. Lip GY. Fibrinogen and cardiovascular disorders. QJM. 1995;88:155-65.
50. Wilhemsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-5.
51. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and the risk of cardiovascular disease: the Framingham study. JAMA. 1987;258:1183-6.
52. Eber B, Schumacher M. Fibrinogen: its role in the hemo-static regulation in atherosclerosis. Semin Thromb Hemost. 1993;19:104-7.
53. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fi brinogen genotype in determining plasma fi brino-gen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost. 1993; 70:915-20.
54. Yu Q, Safavi F, Roberts R, Marian AJ. A variant of the beta fi brinogen is a genetic risk factor for coronary artery disease and myocardial infarction. J Invest Med. 1996;44:154-9.
55. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease and myocardial infarction: the ECTIM Study. Circulation. 1996;93:440-9.
56. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, et al. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction: the ECTIM Study. Arterio-scler Thromb. 1993;13:886-91.
57. Bozdemir V, Kirimli O, Akdeniz B, Aslan A, Kala V, Ozel E, et al. Beta-fibrinogen 455 G/A gene polymorphism is associated with the left atrial thrombus and severe spontaneous echo contrast in atrial fibrillation. Eur Heart J. 2008;29(abst suppl):259.
58. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94: 271-305.
59. Mikkola H, Syrjala M, Rasi V, Vahtera E, Hamalainen E, Peltonen L, et al. Defi ciency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 1994; 84:517-25.
60. Kohler HP, Stickland MH, Ossei-Gernig N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 1998;79:8-13.
61. Aleksic N, Ahn C, Wang YW, Juneja H, Folsom AR, Boerwinkle E, et al. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 2002;22:348-52.
62. Corral J, González-Conejero R, Iniesta JA, Rivera J, Martínez C, Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica. 2000;85: 293-7
63. Ariëns RAS, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fi brin clot formation and effects of genetic polymorphism. Blood. 2002;100:743-54.
64. Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. 1998;92:2766-70
65. Ariëns RAS, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fi brin structure. Blood. 2000;96:988-95.
66. Balogh I, Szöke G, Kárpáti L, Wartiovaarar U, Katona E, Komáromi I, et al. Val34Leu polymorphism of plasma FXIII: biochemistry and epidemiology in familial throm-bophilia. Blood. 2000;96:2479-86
67. Marín F, Corral J, Roldán V, González-Conejero R, del Rey ML, Sogorb F, et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and infl ammatory state associated with atrial fibrillation. J Mol Cell Cardiol. 2004;37:699-704.
68. Hart RG, Halperin JL. Atrial fibrillation and thromboem-bolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131:688-95.
69. Kim SY, Jeitner TM, Steinert PM. Transglutaminases in disease. Neurochem Int. 2002;40:85-103
70. Roldán V, Marín F, González-Conejero R, García-Honrubia A, MartíS, Alfaro A, et al. Factor VII-323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the pro-thrombotic state and stroke risk. Ann Med. 2008;40:553-9.
71. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3 ′-untranslated region of the prothrombin gene is associated with elevated plasma pro-thrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-703.
72. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210A G to A prothrombin variant. Thromb Haemost. 1998;79: 706-8.
73. Redondo M, Watzke HH, Stucki B, Sulzer I, Biasiutti FD, Binder BR, et al. Coagulation factors II, V, VII, and X, prothrombin gene 20210G-A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:1020-5.
74. Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210G/A prothrombin gene mutation: premature coronary artery disease. Thromb Haemost. 1998;80:878-80.
75. Russo G, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, et al. G20210A prothrombin gene polymorphism and prothrombin activity subjects with or without angio-graphically documented coronary artery disease. Circulation. 2001;103:2436-40.
76. Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor V G1691A gene transition and coronary heart disease. Thromb Haemost. 1999;81:208-13.
77. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-50.
78. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;91:3562-5.
79. Hatzinikolau-Kotsakou E, Kartasis Z, Tziakas D, Hotidis A, Stakos D, Tsatalas K, et al. Atrial fibrillation and hyperco-agulability: dependent on clinical factors or/and on genetic alterations? J Thromb Thrombolys. 2003;16:155-61.
80. Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyák K, van Der Meer J, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med. 2001;135:322-7.
81. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Eng J Med. 1995;332:912-7.
82. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-4.
83. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-6.
84. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547-53.
85. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, et al. Factor VII polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscl Thromb Vasc Biol. 1996;16:72-6.
86. Pollak ES, Hung HL, Godin W, Overton GC, High KA. Functional characterization of the human factor VII 5 ′-fl anking region. J Biol Chem. 1996;19:1738-47.
87. Sacchi E, Tagliabue L, Scoglio R, Baroncini C, Coppola R, Bernardi F, et al. Plasma factor VII levels are infl uenced by a polymorphism in the promoter region of the FVII gene. Blood Coagul Fibrinolysis. 1996;72:114-7.
88. Bernardi F, Arcieri P, Bertina RM, Chiarotti F, Corral J, Pinotti M, et al. Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscl Thromb Vasc Biol. 1997;17:2548-53.
89. Corral J, Iniesta JA, González-Conejero R, Villalón M, Vicente V. Polymorphism of clotting factors modify the risk for primary intracraneal haemorrhage. Blood. 2001;97: 2979-82.
90. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost. 2001;86:189-97.
91. Baungartner HR. Platelet interaction with collagen fi brils in fl owing blood: I. Reaction of human platelets with alpha-chymotrypsin-digested subendothelium. Thromb Haemost. 1977;37:1-16.
92. Sixma JJ, van Zanten H, Huizinga EG, van der Plas RM, Verkley M, Wu Y P. Platelet adhesion to collagen: an update. Thromb Haemost. 1997;78:434-8.
93. Alberio L, Dale GL. Flow cytometric analysis of platelet activation by different collagen types present in the vessel wall. Br J Haematol. 1998;102:1212-8.
94. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood. 1997;89:1939-43.
95. Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function-effect in thromboembolic diseases. Thromb Haemost. 1999;81:951-6.
96. Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycopro-tein IIb/IIIa complex. Thromb Haemost. 1994;72:1-15.
97. Shattil SJ. Function and regulation of the β 3 integrins in hemostasis and vascular biology. Thromb Haemost. 1995; 74:149-55.
98. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-9.
99. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-4.
100. Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, Marz W, et al. Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost. 1998;79:731-5.
101. Zotz RB, Winkelmann BR, Muller C, Boehm BO, Marz W, Scharf RE. Association of polymorphisms of platelet membrane integrins alpha IIb(beta)3 (HPA-1b/Pl) and alpha2(beta)1 (alpha807TT) with premature myocardial infarction. J Thromb Haemost. 2005;3:1522-9.
102. Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela A, Dardik R, et al. Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1(Leu33Pro) polymorphism. Stroke. 2001;32:2753-8.
103. Cole VJ, Staton JM, Eikelboom JW, Hankey GJ, Yi Q, Shen Y, et al. Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. J Thromb Haemost. 2003;1:963-70.
104. Kaetzel MA, Hazarika P, Dedman JR. Differential tissue expression of three 35-kDa annexin calcium-dependent phospholipid binding proteins. J Biol Chem. 1989;264: 14463-70.
105. Van Heerde WL, de Groot PG, Reutelingsperger C. The complexity of the phospholipid binding protein annexin V. Thromb Haemost. 1995;73:172-9.
106. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation. 1997;96:2339-47.
107. Cookson BT, Engelhardt S, Smith C, Bamford HA, Prochazka M, Tait JF. Organization of the human annexin V (ANX5) gene. Genomics. 1994;20:463-7.
108. Van Heerde W, Jumilly AL, Lux P, Meyer K. Mutations in the annexin V gene, a new risk factor for venous thrombosis? [abstract no. 1691]. Thromb Haemost. 1999;5:537.
109. Gonzalez-Conejero R, Corral J, Roldán V, Martinez C, Marin F, Rivera J, et al. A common polymorphism in the annexin V Kozak sequence (1C/T) increases effi ciency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood. 2002;100:2081-6.
110. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydro-folate reductase. Nat Genet. 1995;10:111-3.
111. Eriksson P, Kallin B, van ' t Hooft FM, Båvenholm P, Hamsten A. Allele-specifi c increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92: 1851-5.
112. Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, et al. The-174G/C interleukin-6 polymorphism infl uences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an infl ammatory complication? Circulation. 2003;108 Suppl 1:II195-9.
113. Goracy I, Cyryłowski L, Kaczmarczyk M, Fabian A, Koziarska D, Goracy J, et al. C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of ischemic stroke in Polish subjects. J Appl Genet. 2009; 50:63-7.
114. Kawamoto R, Kohara K, Oka Y, Tomita H, Tabara Y, Miki T. An association of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and ischemic stroke. J Stroke Cerebrovasc Dis. 2005;14:67-74.
115. Adamski MG, Turaj W, Slowik A, Wloch-Kopec D, Wolkow P, Szczudlik A. A-G-4G haplotype of PAI-1 gene polymorphisms-844 G/A, HindIII G/C, and-675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol Scand. 2009;120:94-100.
116. Jood K, Ladenvall P, Tjärnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke. 2005;36:2077-81
117. Marín F, González-Conejero R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009; 54:1041-57.
118. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet. 2000;355:1358-61.
119. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857-65.
120. Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692-711.
121. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5:54-9.
122. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254: 628-31.
123. Linder MW, Looney S, Adams JE 3rd, Johnson N, Antonino-Green D, Lacefield N, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002;14:227-32.
124. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96:1816-9.
125. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding Complications. Lancet. 1999;353:717-9.
126. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-8.
127. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000;84: 775-8.
128. Peyvandi F, Spreafi co M, Siboni SM, Moia M, Mannucci PM. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther. 2004;75:198-203.
129. Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, et al. The risk of overanticoagula-tion in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics. 2004;14:27-33.
130. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-12.
131. Pérez-Andreu V, Roldán V, Antón AI, García-BarberáN, Corral J, Vicente V, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113:4977-9.
132. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009;18:3758-68.
133. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on tran-scriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-93.
134. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008;112: 1013-21
135. González-Conejero R, Corral J, Roldán V, Ferrer F, Sánchez-Serrano I, Sánchez-Blanco JJ, et al. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of aceno-coumarol. J Thromb Haemost. 2007;5:1701-6.
136. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor defi ciency type 2. Nature. 2004;427:537-41.
137. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientifi c, and clinical issues. J Thromb Thrombolysis. 2008;25:45-51.
138. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confi rms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433.
139. King CR, Porche-Sorbet RM, Gage BF, Ridker PM, Renaud Y, Phillips MS, et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol. 2008;129:876-83.
140. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358:999-1008.
141. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-31.
142. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large Influence on warfarin maintenance dose. Blood. 2008;112:1022-7.
143. International Warfarin Pharmacogenetic Consortium; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360: 753-64.
144. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113: 784-92
145. Pérez-Andreu V, Roldán V, López-Fernández MF, Antón AI, Alberca I, Corral J, et al. Pharmacogenetics of aceno-coumarol in patients with extreme dose requirements. J Thromb Haemost. 2010;8:1012-7.
146. Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. 2010;8:95-100.